Pharma firm Glenmark today said its US-based subsidiary Glenmark Generics has received a final approval from the US health regulator FDA for Calcipotriene ointment used to treat psoriasis.
The company has received an approval from the US Food and Drug Department for Calcipotriene ointment, Glenmark said in a statement.
Glenmark's approved version of calcipotriene ointment is used for the treatment of plaque psoriasis in adults, the release added.
